CollPlant details VergenixSTR distribution expansion in Europe

Accepted by SEC EDGAR 09/15/2025 - 07:24 AM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. submitted a Form 6-K as a foreign private issuer, noting that it issued a press release on September 15, 2025 titled “CollPlant Expands the Distribution of its VergenixSTR Product in Europe.”

This filing mainly serves to formally furnish that press release to investors and the market under U.S. securities rules. It highlights CollPlant’s focus on expanding access to its VergenixSTR product in European markets, but does not itself include financial results or transaction details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CollPlant Biotechnologies Ltd. (CLGN) report in this Form 6-K?

CollPlant Biotechnologies Ltd. reported that on September 15, 2025 it issued a press release titled “CollPlant Expands the Distribution of its VergenixSTR Product in Europe.”

What is the main topic of CollPlant (CLGN)'s September 2025 press release referenced in the 6-K?

The press release focuses on CollPlant expanding the distribution of its VergenixSTR product in Europe.

Does this CollPlant (CLGN) Form 6-K include financial results or earnings data?

No. The Form 6-K only notes the issuance of a press release about VergenixSTR distribution expansion in Europe and does not include financial or earnings data in the excerpt provided.

When was the CollPlant (CLGN) Form 6-K signed and by whom?

The Form 6-K was dated September 15, 2025 and signed on behalf of CollPlant Biotechnologies Ltd. by Eran Rotem, Deputy CEO and Chief Financial Officer.

Why does CollPlant (CLGN) furnish this press release on Form 6-K?

As a foreign private issuer, CollPlant uses Form 6-K to furnish important company information, such as the press release on VergenixSTR distribution expansion, under U.S. securities regulations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 15, 2025, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Expands the Distribution of its VergenixSTR Product in Europe”.

Attached hereto and incorporated by reference herein are the following exhibits:

99.1

Press Release, dated September 15, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.

Date: September 15, 2025	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

Source: View Original Filing on SEC EDGAR